XML 114 R5.htm IDEA: XBRL DOCUMENT v3.20.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - CAD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Operating activities    
Net loss $ (52,013,186) $ (22,710,624)
Add (deduct) items not affecting cash    
Depreciation and amortization 3,146,680 183,194
Impairment of property, plant and equipment and right-of-use asset 243,468  
Listing expense   7,991,791
Interest expense 206,454  
Share-based payments 16,061,319 6,440,406
Change in fair value of other investments 11,669,157 (17,564,529)
Change in fair value of derivative liability 3,568,305  
Change in fair value adjustments on inventory sold 22,249  
Change in fair value of biological assets 682,739  
Loss on settlement of financial liability 24,810  
Allowance for impairment of Auxly funds   7,499,977
Changes in non-cash working capital balances    
Trade and other receivables (1,079,067) (664,610)
Prepaid expenses and deposits 39,892 (99,264)
Inventories (942,939)  
Biological assets (682,739)  
Trade and other payables 825,120 433,754
Cash used in operating activities (18,227,738) (18,489,905)
Investing activities    
Cash acquired from acquisition Prismic Pharmaceuticals Inc. 2,329  
Reverse Takeover Transaction   2,041,501
Proceeds from sale of investments 614,520  
Purchase of other investments   (7,999,991)
Purchase of property, plant and equipment (534,118) (4,032,832)
Additions to intangible assets (389,640)  
Cash used in investing activities (306,909) (9,991,322)
Financing activities    
Repayment of lease obligation (56,207)  
Proceeds from issuance of shares 4,593,777 44,987,422
Share issue costs (32,705) (3,768,381)
Proceeds from exercise of share options 732,598 2,857,050
Proceeds from warrants exercised 94,991 800,078
Cash provided by financing activities 5,332,454 44,876,169
Net (decrease) increase in cash during the year (13,202,193) 16,394,942
Cash, beginning of year 21,134,930 4,739,988
Cash, end of year $ 7,932,737 $ 21,134,930